Basel / San Francisco | January 2026
Novartis has expanded its precision oncology strategy with a global license and acquisition agreement for a radioligand peptide program from China’s PepLib Biotech. Under the terms, Novartis obtained exclusive worldwide rights to the peptide‑based radioligand therapy (RLT) asset, positioning the company to advance the program through development and potential commercialization. The transaction was disclosed during JPM 2026, where Novartis reaffirmed its leadership in next‑generation cancer treatments.
Strategic Push into Radioligand Therapies
Radioligand therapy is a rapidly evolving class of targeted oncology treatments that deliver radioactive payloads directly to tumor cells via tumor-specific ligands. Novartis has been a leading supporter of RLT innovation, with existing programs and approved therapies in this modality. The newly acquired program from PepLib is expected to complement this portfolio and enhance Novartis’ ability to pursue precision radiopharmaceutical oncology strategies.
Under the deal, Novartis made an upfront cash payment of approximately USD 50 million, with additional development, regulatory, and sales milestone payments and tiered royalties on future global net sales contingent on the program’s progress. PepLib retains the opportunity to receive these future payments as the asset advances.
PepLib’s Asset and Value Creation Potential
The radioligand peptide asset was developed internally by PepLib prior to the agreement. Novartis will now assume responsibility for further development and clinical evaluation, leveraging its extensive global R&D capabilities and regulatory experience to move the program forward. The asset is expected to enrich Novartis’ RLT pipeline by providing a differentiated targeted therapy that may address oncologic indications where precise delivery of radiation could improve treatment outcomes.
PepLib’s peptide discovery expertise, combined with Novartis’ development infrastructure, reflects a growing industry trend of strategic asset collaborations and acquisitions that accelerate access to promising therapeutic modalities.
JPM 2026 Context: Continued Oncology Focus
The announcement of the PepLib radioligand program deal at JPM 2026 highlights the ongoing emphasis on oncology innovation and targeted therapies at this year’s conference. Novartis’ move builds on broader industry momentum toward capturing value in modalities such as RLTs, bispecifics, and other precision platforms, as companies seek differentiated mechanisms to address unmet patient needs.
Strategic Outlook
Novartis’ acquisition of the radioligand program from PepLib signals a firm commitment to maintaining leadership in precision oncology, particularly in advanced radiopharmaceutical approaches. As the program transitions into Novartis’ development pipeline, stakeholders will be watching for clinical progress, regulatory milestones, and potential future partnerships that could expand the asset’s therapeutic reach.
BioNext Market Insights – Strategic Takeaway:
Novartis’ move to secure exclusive rights to a peptide‑based radioligand program at JPM 2026 underscores the high strategic value placed on targeted radiopharmaceutical oncology assets, reinforcing the company’s competitive stance in next‑generation cancer treatment innovation.
By